Moleculin Biotech, Inc. (NASDAQ:MBRX) Short Interest Update

Moleculin Biotech, Inc. (NASDAQ:MBRX) was the recipient of a significant decline in short interest during the month of February. As of February 27th, there was short interest totaling 191,156 shares, a decline of 56.7% from the February 12th total of 441,371 shares. Currently, 9.6% of the shares of the stock are short sold. Based on an average daily volume of 435,180 shares, the days-to-cover ratio is currently 0.4 days. Based on an average daily volume of 435,180 shares, the days-to-cover ratio is currently 0.4 days. Currently, 9.6% of the shares of the stock are short sold.

Moleculin Biotech Stock Performance

NASDAQ MBRX traded down $0.01 during mid-day trading on Thursday, reaching $2.02. 99,455 shares of the stock were exchanged, compared to its average volume of 189,314. The stock has a market capitalization of $4.12 million, a PE ratio of -0.06 and a beta of 1.73. Moleculin Biotech has a 1-year low of $1.79 and a 1-year high of $33.00. The business’s fifty day simple moving average is $3.66 and its 200 day simple moving average is $7.53.

Analysts Set New Price Targets

Several research firms have recently issued reports on MBRX. HC Wainwright reaffirmed a “buy” rating and set a $22.00 price target (up from $4.00) on shares of Moleculin Biotech in a research note on Thursday, December 11th. Roth Mkm reiterated a “buy” rating on shares of Moleculin Biotech in a report on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Moleculin Biotech in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $61.00.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC bought a new position in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned 1.11% of Moleculin Biotech at the end of the most recent quarter. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.